Von Hoff named TGen executive VP

Dr. Daniel Von Hoff, renowned cancer researcher and former director of the Arizona Cancer Center, has been named executive vice president of TGen.

Von Hoff wears many hats these days. Two months ago, he stepped down as leader of the Arizona Cancer Center to become director of Arizona Health Sciences Center's Cancer Therapeutics Program. He serves as director of TGen's Translational Drug Development Division and head of its Pancreatic Cancer Research Program. Von Hoff is also vice president of IGC, and is a professor in UA's Department of Medicine, Molecular and Cellular Biology, and Pathology.

So many positions would seem to suggest that Von Hoff's efforts are at risk of being diluted; not so, he says. As he told David Wichner of the Arizona Daily Star, his goal remains the same: to help coordinate statewide research and to work on his own projects.

"It doesn't change the job, to get the drugs to the people," he said.

Indeed, each position Von Hoff holds provides him with one more platform from which to organize statewide efforts. As he told the Star, such coordination will allow Arizona's universities, in conjunction with TGen, to win more research work than the individual universities ever could on their own.

"We're not competing," Raymond Woosley, University of Arizona's vice president of health sciences, told the Star. "The state is already working together."

---

For more information:

"Von Hoff of UA takes on a wider TGen role," Arizona Daily Star, "Bio File," 10/16/2003

"TGen reunites cancer researchers," Arizona Republic, 10/16/2003

"UA Professor Daniel D. Von Hoff MD accepts additional role as Director of Translational Drug Development at TGen: Cancer Drug Development to be Primary Focus," News@TGen.org (http://www.tgen.org)

Cancer Center director still driven by bench, bedside